5 results
The current study is being conducted to determine whether long-term dual-antiplatelet therapy with ticagrelor in combination with ASA (recommended daily dose 75-100 mg) is beneficial in patients with history of MI (1-3 years ago) and additional risk…
The primary objective of this study is to assess the efficacy and safety of 10600 nm fractional laser therapy for the treatment of different types of scars.
To investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.
To evaluate safety of 3-months versus standard 12-months of DAPT